Modality
Nanobody
MOA
AuroraAi
Target
USP1
Pathway
Fibrosis
PTSD
Development Pipeline
Preclinical
~Feb 2016
→ ~May 2017
Phase 1
Aug 2017
→ Aug 2026
Phase 1Current
NCT07848908
2,178 pts·PTSD
2017-08→TBD·Not yet recruiting
NCT08892175
1,839 pts·PTSD
2023-04→2026-08·Active
4,017 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-08-235mo awayInterim· PTSD
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
P1
Not yet…
P1
Active
Catalysts
Interim
2026-08-23 · 5mo away
PTSD
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07848908 | Phase 1 | PTSD | Not yet recr... | 2178 | SRI-4 |
| NCT08892175 | Phase 1 | PTSD | Active | 1839 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| ABB-2476 | AbbVie | Phase 1/2 | USP1 | |
| TAK-5300 | Takeda | Phase 1 | SMN2 | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| BGN-6990 | BeiGene | Phase 2/3 | BCMA | |
| Semasacituzumab | Jazz Pharma | Phase 2 | AHR | |
| ILM-2412 | Illumina | Phase 3 | PLK4 | |
| Capirapivir | TG Therapeutics | Approved | JAK2 |